Metabolic Alkalosis: Pathogenesis, Diagnosis via Urine Chloride, and Management

Key Physiologic Concept: Generation vs. Maintenance

A critical conceptual framework distinguishes between two phases of metabolic alkalosis:

1. Generation Phase: The initial event that causes HCO₃⁻ to accumulate
2. Maintenance Phase: The factors that prevent the kidney from simply excreting the excess HCO₃⁻

Both phases must be present for alkalosis to persist. Understanding this distinction is essential for effective treatment.

Expected Respiratory Compensation

In pure metabolic alkalosis, the respiratory system attempts to compensate by increasing PCO₂ (hypoventilation). The expected compensatory response follows Winter’s formula:

Expected PCO₂ = 0.9 × [HCO₃⁻] + 16 ± 2

Alternatively, for every 1 mEq/L increase in serum HCO₃⁻, PCO₂ rises approximately 0.7 mmHg (range 0.6–0.9 mmHg depending on respiratory reserve).

• If measured PCO₂ is lower than expected: concurrent respiratory alkalosis exists
• If measured PCO₂ is higher than expected: concurrent respiratory acidosis exists
• If measured PCO₂ matches expected: pure metabolic alkalosis

Phase 1: Generation of Alkalosis

Metabolic alkalosis is generated through three primary mechanisms:

Phase 2: Maintenance of Alkalosis

Once HCO₃⁻ is elevated, why doesn’t the kidney simply excrete it? Several factors prevent appropriate renal HCO₃⁻ excretion:

Why Urine Chloride Over Urine Sodium?

The classic teaching of using urine sodium to assess volume status breaks down in metabolic alkalosis. Here’s why:

Example: - Patient with vomiting-induced alkalosis: Urine Na+ might be 60 mEq/L (falsely suggesting adequate volume status) - BUT urine Cl⁻ is 8 mEq/L (correctly indicating chloride depletion and volume contraction) - The “extra” Na⁺ is accompanying HCO₃⁻ in urine

Clinical implications: - Use spot urine chloride, not sodium, for classification - Random urine specimens are acceptable (not 24-hour collection needed) - Compare urine Cl⁻ to cutoff of 20 mEq/L

Classification: Chloride-Responsive vs. Chloride-Resistant

Urine chloride concentration divides metabolic alkalosis into two pathophysiologically distinct groups that require different treatments.

Urine Chloride Interpretation Algorithm

Metabolic Alkalosis Diagnosed
  ↓
Measure spot urine chloride (random urine acceptable)
  ↓
UCl < 20 mEq/L                        UCl > 20 mEq/L
     ↓                                    ↓
Chloride-responsive                   Chloride-resistant
     ↓                                    ↓
Identify cause:                        Check BP and
- Vomiting/NG suction                  renin/aldosterone
- Recent diuretics
- Post-hypercapnic
- GI Cl⁻ losses
     ↓                                    ↓
→ Treat with saline,              → If HTN: aldosteronism/
  KCl, correct K⁺/Mg²⁺               other renal cause
                                   → If normotensive:
                                      Bartter/Gitelman or
                                      severe K⁺/Mg²⁺ depletion

Vomiting and Nasogastric Suction

Pathophysiology:

Gastric fluid is rich in hydrochloric acid (HCl concentration approximately 150 mEq/L H⁺ and 150 mEq/L Cl⁻). Loss of gastric contents removes hydrogen and chloride ions in a 1:1 ratio, creating a double deficit.

• H⁺ loss: Immediate reduction in systemic acid load → HCO₃⁻ rises
• Cl⁻ loss: Creates chloride depletion despite ongoing vomiting
• Volume depletion: Loss of fluid stimulates RAAS
• Aldosterone activation: Volume depletion triggers renin release → angiotensin II → aldosterone
  • Aldosterone increases Na⁺ reabsorption (via ENaC)
  • Na⁺ reabsorption couples to H⁺ secretion in α-intercalated cells
  • Results in “paradoxical aciduria” — urine pH paradoxically LOW despite systemic alkalosis, because each H⁺ secreted carries positive charge offset by K⁺ and NH₄⁺ losses
• Hypokalemia: Both from GI losses and ongoing renal K⁺ wasting via aldosterone and H⁺/K⁺-ATPase
• Hypomagnesemia: Often concurrent, perpetuates K⁺-wasting and alkalosis

Clinical Features: - UCl < 10 mEq/L (very low chloride) - Volume depletion signs (orthostasis, dry mucosa, concentrated urine) - Hypokalemia (K⁺ often < 3.0 mEq/L) - Metabolic alkalosis pH 7.50–7.70

Treatment: - Discontinue vomiting source (antiemetics, repair anatomic cause) - Normal saline (0.9% NaCl): Provides both Na⁺ and Cl⁻ to replete chloride deficit - Calculated Cl⁻ deficit ≈ (normal Cl⁻ 103 mEq/L − measured Cl⁻) × weight in kg × 0.2 (distribution factor) - Example: 70 kg patient with Cl⁻ 85 mEq/L → deficit ≈ 252 mEq → ≈ 2.8 L NS - Potassium replacement: KCl 20–40 mEq IV or PO (if continuing NG losses, may need frequent dosing) - Target K⁺ > 3.5 mEq/L (hypokalemia perpetuates alkalosis) - Magnesium repletion: Check Mg²⁺ and supplement if < 1.8 mg/dL - H₂ blocker or PPI: If ongoing NG suction → reduces gastric HCl production - Fluid restriction: If SIADH concurrent (rare but possible with volume depletion)

Diuretic-Induced Metabolic Alkalosis

Mechanism:

Loop and thiazide diuretics cause acute sodium, potassium, and chloride wasting by blocking their reabsorption in the thick ascending limb (loop) or distal convoluted tubule (thiazides).

• Acute phase (while taking diuretic): Patients have elevated urine sodium and chloride
• Post-diuretic phase (after stopping medication):
  • Kidneys have lost significant NaCl and KCl stores
  • Volume contraction activates RAAS
  • Chloride depletion prevents adequate HCO₃⁻ excretion
  • Hypokalemia perpetuates H⁺ secretion
  • Metabolic alkalosis becomes apparent and persistent despite stopping diuretic

Risk Factors: - Chronic diuretic use (especially loop diuretics for heart failure, hepatic cirrhosis with ascites) - Inadequate electrolyte monitoring - Concurrent vomiting or diarrhea - High sodium diet (increases urinary sodium losses during diuretic use)

Clinical Presentation: - UCl < 20 mEq/L (chloride depletion from diuretic-induced losses) - Volume depletion or euvolemia depending on baseline fluid status - Hypokalemia (often profound) - Metabolic alkalosis typically pH 7.50–7.60

Treatment: - Discontinue or reduce diuretic if possible (adjust for underlying condition: CHF, cirrhosis, HTN) - Saline replacement: Normal saline at rate of 150–300 mL/hour if volume-depleted - KCl supplementation: 40–60 mEq/day in divided doses - Acetazolamide: 250–500 mg daily or BID if diuretic cannot be stopped or patient is euvolemic - Works by promoting renal HCO₃⁻ excretion at level of proximal tubule - Does NOT provide chloride → use ONLY in euvolemic/hypervolemic patients (avoid if volume-depleted) - Can worsen hypokalemia → give with KCl - Spironolactone: Consider if patient still requires diuresis (potassium-sparing) and can tolerate - Blocks aldosterone → reduces H⁺ and K⁺ secretion - More effective if aldosterone is elevated (secondary to volume depletion)

Post-Hypercapnic Metabolic Alkalosis

Pathophysiology:

Chronic hypercapnia (elevated PCO₂) triggers renal adaptation to maintain pH within acceptable range.

1. Chronic respiratory acidosis (chronic COPD, chronic hypoventilation, etc.):
   • Elevated PCO₂ and H⁺ levels for weeks to months
   • Kidney compensates by:
     • Increasing HCO₃⁻ reabsorption in proximal tubule (via increased carbonic anhydrase activity)
     • Increasing H⁺ secretion in collecting duct (via increased H⁺-ATPase expression)
     • Increased ammoniagenesis (NH₃ excretion paired with H⁺)
   • Serum HCO₃⁻ gradually rises (typically to 30–35 mEq/L in chronic stable state)
2. Acute correction of hypercapnia (mechanical ventilation initiated, COPD exacerbation treated):
   • PCO₂ rapidly normalized or reduced below baseline
   • BUT the kidneys’ enhanced HCO₃⁻ reabsorption and H⁺ secretion mechanisms persist
   • Result: Elevated HCO₃⁻ without elevated PCO₂ = metabolic alkalosis
3. Resolution: Alkalosis persists until:
   • Chloride stores are repleted (normal saline)
   • Hypokalemia corrected (KCl)
   • Hypomagnesemia corrected
   • Then kidney can “reset” its acid-base set point

Clinical Scenario: 70-year-old with COPD on home oxygen, baseline ABG: pH 7.30, PCO₂ 65, HCO₃⁻ 32 (compensated respiratory acidosis). Hospitalized for pneumonia, intubated, mechanically ventilated with tight control. Next day ABG: pH 7.55, PCO₂ 38, HCO₃⁻ 33 = post-hypercapnic metabolic alkalosis.

Treatment: - Chloride repletion: Normal saline (even if euvolemic) - Potassium repletion: KCl if K⁺ depleted - Magnesium repletion: Check Mg²⁺ - Allow ventilation adjustment: Do NOT over-ventilate further; use permissive mild hypercapnia if possible - Acetazolamide: Helpful if patient cannot tolerate saline (CHF, ARDS, etc.) - Promotes HCO₃⁻ excretion - May require 500 mg BID to achieve effect - Slow correction: Allow 24–48 hours for HCO₃⁻ to normalize to avoid rapid alkalemia complications

Milk-Alkali Syndrome

Definition: Triad of: 1. Metabolic alkalosis 2. Hypercalcemia 3. Renal insufficiency (AKI)

Caused by excessive intake of absorbable alkali (traditionally milk + alkali antacids; now often calcium supplements + alkali or PPI use with high-dose Ca²⁺).

Pathophysiology:

• Alkali load: Excessive CaCO₃ or sodium bicarbonate intake
• Calcium absorption: High Ca²⁺ absorbed in GI tract → hypercalcemia
• Hypercalcemia effects:
  • Increases filtered load of calcium
  • Hypercalcemia impairs renal concentrating ability (nephrogenic diabetes insipidus) → polyuria
  • Polyuria causes volume depletion → activates RAAS → alkalosis perpetuation
  • Hypercalcemia decreases GFR (direct vasoconstrictive effect, tubular toxicity)
• Renal insufficiency (from chronic hypercalcemia):
  • Nephrocalcinosis develops
  • Chronic kidney disease → further reduced GFR
  • Reduced GFR → reduced HCO₃⁻ excretion → persistent alkalosis

Clinical Features: - Metabolic alkalosis (UCl variable, often < 20 mEq/L initially) - Serum calcium elevated (corrected Ca²⁺ > 10.5 mg/dL, often > 12 mg/dL) - Serum creatinine elevated or rising (AKI) - History of excessive antacid use, calcium supplement abuse, or high-dose PPI + calcium - Urine calcium elevated

Modern Epidemiology: Formerly (1900s–1950s) caused by milk + sodium bicarbonate antacids. Now increasingly recognized in: - Postmenopausal women taking high-dose calcium supplements (> 3000 mg/day) - Patients on chronic PPI therapy (hypochlorhydria → increased Ca²⁺ absorption) combined with aggressive calcium supplementation - Vitamin D supplementation with excessive calcium intake

Treatment (requires multi-pronged approach):

1. Discontinue alkali and excess calcium: Cease all CaCO₃, Na⁺HCO₃, and reduce Ca²⁺ supplementation to RDA (1000–1200 mg/day)
2. Volume repletion: Normal saline (careful in setting of renal insufficiency; may require reduced rate)
3. Calciuria promotion: Loop diuretic (furosemide) may be added to increase urine calcium excretion after volume repletion
4. Hydration: Adequate fluid intake to maintain urine output and dilute urine calcium
5. Corticosteroids: Prednisone 20–40 mg daily (alternative to diuretic) if renal function severely impaired
   • Reduces intestinal calcium absorption
   • Increases urinary calcium excretion
   • Can be gradually tapered as calcium normalizes
6. Dialysis: Reserved for severe renal failure (Cr > 3 mg/dL) if above measures fail

Prognosis: If caught early (before chronic nephrocalcinosis develops), complete resolution possible. If chronic changes present, residual renal insufficiency may persist.

Bartter Syndrome

Definition: Rare autosomal recessive disorder characterized by renal salt wasting, hypokalemic metabolic alkalosis, normal blood pressure, and normotensive hyperreninemia.

Genetics and Pathophysiology:

Caused by mutations in genes encoding proteins of the thick ascending limb (TAL) of loop of Henle, mimicking chronic loop diuretic use.

• Type 1 Bartter (NKCC2 mutations): Sodium-potassium-chloride cotransporter defect
• Type 2 Bartter (ROMK mutations): Renal outer medullary potassium channel defect
• Type 3 Bartter (ClC-Kb mutations): Chloride channel defect
• Types 4–5 Bartter: Rarer (calcium-sensing receptor, other transporters)

Key Features: - Polyuria with isosthenuria (inability to concentrate urine) - Hypokalemic metabolic alkalosis (from renal H⁺ and K⁺ wasting) - Hypercalciuria (high urine calcium, opposite of Gitelman) - Hypercalcemia may develop - Normal or low blood pressure (distinguishes from primary aldosteronism) - Elevated plasma renin and aldosterone despite normal BP (secondary hyperaldosteronism from volume depletion) - Urine chloride > 20 mEq/L (chloride-resistant alkalosis) - Growth retardation (in children) - Sensorineural hearing loss (in Type 4 Bartter with β-subunit mutations)

Clinical Presentation:

Depending on type and severity: - Neonates with Type 1–3: Severe polyuria, hypernatremia (from insensible losses), failure to thrive - Older children/adolescents: Polydipsia, polyuria, muscle weakness (K⁺ wasting), growth stunting

Diagnosis: - Labs: Hypokalemia, metabolic alkalosis, elevated plasma renin/aldosterone, hypercalciuria - Imaging: Ultrasound may show nephrocalcinosis (calcium deposits in renal parenchyma) - Genetic testing: Confirm specific mutation - Trial of NSAIDs: Dramatic response to indomethacin (see treatment)

Treatment: - NSAIDs (indomethacin, ibuprofen): Inhibit renal prostaglandin synthesis → reduce renin release and reverse many features - Indomethacin 1–2 mg/kg/day (divided doses) - Often results in dramatic clinical improvement - Risk: NSAID-induced renal failure (especially in setting of existing polyuria and volume loss) - Potassium-sparing diuretics: Amiloride (blocks ENaC), spironolactone (blocks aldosterone) - KCl supplementation: High-dose K⁺ (60–120 mEq/day) often required - Magnesium supplementation: Often deficient - Sodium and fluid intake: Liberal to maintain euvolemia and reduce RAAS activation - Thiazide diuretics: Paradoxically may improve some features (reduces hypercalciuria via volume contraction stimulating proximal tubule Ca reabsorption)

Gitelman Syndrome

Definition: Autosomal recessive disorder from mutations in thiazide-sensitive sodium-chloride cotransporter (NCCT/SLC12A3) in distal convoluted tubule, mimicking chronic thiazide diuretic use.

Pathophysiology:

The DCT normally reabsorbs 5–10% of filtered NaCl via NCCT. Loss of NCCT function causes: - Renal sodium and chloride wasting - Secondary hyperaldosteronism (from volume depletion/hyponatremia) - Hypokalemia (from aldosterone-driven K⁺ secretion) - Metabolic alkalosis (from K⁺ and H⁺ wasting)

Key Distinguishing Features (vs. Bartter):

Clinical Presentation: - Adolescence or early adulthood (many diagnosed in 20s–30s) - Hypokalemia (K⁺ often < 3.0 mEq/L) - Hypomagnesemia (Mg²⁺ < 1.5 mg/dL) - Muscle cramps and weakness - Metabolic alkalosis - Occasionally cardiac arrhythmias (from concurrent hypokalemia and hypomagnesemia)

Diagnosis: - Labs: Hypokalemia, hypomagnesemia, metabolic alkalosis, elevated renin/aldosterone, hypocalciuria (urine Ca < 2 mg/kg/day) - Genetic testing: NCCT mutations - Thiazide diuretic trial: May provide clue (symptoms resemble chronic thiazide use)

Treatment: - Potassium chloride: 40–100 mEq/day (must be generous; many patients require ongoing supplementation) - Magnesium supplementation: Essential; many formulations available (oxide poorly absorbed; try glycinate, citrate) - Target serum Mg²⁺ > 1.8–2.0 mg/dL - Often requires 400–600 mg/day elemental magnesium - NSAIDs: May provide benefit (similar to Bartter) - Amiloride: Potassium-sparing diuretic (blocks ENaC) - Sodium chloride: Liberal salt intake (paradoxically helpful by reducing RAAS activation) - Adequate hydration: Maintain euvolemia

Primary Aldosteronism

Definition: Excessive production of aldosterone by adrenal glands independent of physiologic regulation (RAAS), causing hypertension and hypokalemic metabolic alkalosis.

Types:

• Aldosterone-producing adenoma (APA) (~35–40%): Solitary benign tumor secreting aldosterone
• Idiopathic hyperaldosteronism (IHA) (~50–60%): Bilateral adrenal hyperplasia without discrete adenoma
• Familial hyperaldosteronism (~1%): Rare autosomal dominant (fusion gene CYP11B1/CYP11B2)
• Aldosterone-producing carcinoma (< 1%): Malignant adrenal tumor

Pathophysiology:

Excess aldosterone → mineralocorticoid receptor activation in cortical collecting duct: - Increases epithelial sodium channel (ENaC) expression and activity - Enhanced Na⁺ reabsorption in principal cells - Coupled K⁺ and H⁺ secretion via: - K⁺ secretion via ROMK and BK channels - H⁺ secretion via H⁺-ATPase in α-intercalated cells - Results in: - Hypertension (from Na⁺ and water retention) - Hypokalemia (K⁺ wasting) - Metabolic alkalosis (H⁺ wasting)

Clinical Presentation: - Hypertension (typically resistant to 1–2 antihypertensives) - Hypokalemia (K⁺ < 3.5 mEq/L; symptomatic if severe < 3.0 mEq/L) - Metabolic alkalosis (pH 7.45–7.55, HCO₃⁻ 28–35) - Hypernatremia (mild, Na⁺ often 143–146 mEq/L) - Metabolic alkalosis with UCl > 20 mEq/L (chloride-resistant) - Low plasma renin activity (suppressed by volume expansion from aldosterone) - Elevated plasma aldosterone (absolute value or aldosterone-renin ratio > 20–30)

Diagnosis (Four-step approach):

1. Case detection: Check aldosterone-to-renin ratio (ARR) in hypertensive patient with:
   • Hypokalemia (K⁺ < 3.5)
   • Metabolic alkalosis
   • Resistant hypertension
   • Incidental adrenal mass on imaging
2. Confirmatory testing: If ARR > 20–30 (varies by lab), confirm with:
   • 24-hour urine aldosterone (elevated)
   • Saline suppression test (aldosterone not suppressed after 2 L NS IV)
   • Oral sodium loading (high aldosterone despite Na⁺ loading)
3. Subtype differentiation: Distinguish APA from IHA via:
   • CT/MRI adrenal imaging: Look for nodule
   • Adrenal vein sampling (AVS): Catheterize bilateral adrenal veins, measure aldosterone/cortisol ratio
     • Unilateral excess → suggests APA
     • Bilateral excess → suggests IHA
   • Genetic testing: If familial hyperaldosteronism suspected
4. Target organ assessment:
   • ECG (LVH, arrhythmia risk from hypokalemia)
   • Renal ultrasound (renal artery stenosis if secondary aldosteronism)

Treatment:

• APA (aldosterone-producing adenoma):
  • Surgical adrenalectomy: Curative for unilateral APA
  • Spironolactone: Bridging therapy pre-operatively; lifelong if surgery declined
  • Amiloride: Alternative potassium-sparing diuretic
• IHA (idiopathic hyperaldosteronism):
  • Spironolactone: First-line mineralocorticoid receptor antagonist
    • Dose: 25–100 mg daily (titrate by BP and K⁺ response)
    • Side effects: Gynecomastia, sexual dysfunction (due to androgen receptor antagonism)
    • Monitor K⁺ (risk of hyperkalemia) and renal function
  • Eplerenone: Selective mineralocorticoid antagonist (fewer sex hormone side effects)
    • Dose: 50–100 mg daily
    • More expensive than spironolactone
  • Amiloride: Alternative (ENaC blocker)
    • Dose: 5–10 mg daily
    • Blocks aldosterone’s effect at collecting duct level
    • Monitor K⁺ (hyperkalemia risk)
• Hypokalemia correction:
  • KCl supplementation during MRA titration
  • Once spironolactone/eplerenone/amiloride established, may develop hyperkalemia → requires monitoring
• Hypertension management:
  • Treat to goal BP < 130/80 mmHg
  • Many patients require multiple agents (ACE-I, ARB, CCB, etc.) even with MRA

Licorice and Apparent Mineralocorticoid Excess

Definition and Mechanism:

Glycyrrhizic acid (found in licorice, some chewing tobacco, herbal supplements) inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which normally inactivates cortisol to cortisone in the kidney.

Normal physiology: - Cortisol and aldosterone both bind mineralocorticoid receptor (MR) with equal affinity - 11β-HSD2 inactivates cortisol → cortisone (cannot activate MR) - This selectivity ensures aldosterone is the main physiologic MR agonist

Licorice-induced pathophysiology: - Inhibition of 11β-HSD2 → cortisol not inactivated - Cortisol accumulates in collecting duct - Cortisol activates MR (same as aldosterone) - Results in: - Hypertension (Na⁺ retention) - Hypokalemia (K⁺ wasting) - Metabolic alkalosis (H⁺ wasting) - Suppressed renin and aldosterone (distinguishes from primary aldosteronism)

Clinical Presentation: - Hypertension - Hypokalemia - Metabolic alkalosis with UCl > 20 mEq/L - History of licorice consumption (licorice root tea, black licorice candy, herbal supplements, chewing tobacco) - Low plasma renin and aldosterone (key finding)

Other Genetic Causes of 11β-HSD2 deficiency (rare): - Apparent mineralocorticoid excess (AME): Autosomal recessive mutations in 11β-HSD2 gene - Presents in childhood with severe hypertension and hypokalemia - Suppressed renin and aldosterone

Treatment: - Discontinue licorice products: Complete cessation usually required - Potassium supplementation: KCl until serum K⁺ normalizes - Spironolactone or amiloride: Bridge therapy if needed while stopping licorice - Antihypertensive agents: For BP management; may improve after stopping licorice

Neuromuscular Manifestations

Mechanism: Metabolic alkalosis increases pH → increases ionized (free) calcium by promoting protein binding of Ca²⁺ to serum albumin and other proteins → decreased serum ionized Ca²⁺ → neuromuscular hyperexcitability

Additionally, alkalosis increases cellular hyperpolarization (more negative resting membrane potential) → facilitates action potential generation

Clinical Features: - Tetany: Involuntary muscle contractions, especially perioral and distal extremities - Paresthesias: Tingling in fingers, toes, lips (circumoral) - Muscle weakness: May paradoxically occur with severe alkalosis (despite hyperexcitability at lower pH) - Seizures: In severe alkalosis (pH > 7.70), can cause generalized tonic-clonic seizures - Trousseau sign: Carpopedal spasm when sphygmomanometer cuff inflated (tests for latent tetany) - Chvostek sign: Facial contraction when tapping on facial nerve anterior to earlobe (tests for latent tetany)

Cardiac Manifestations

Mechanism: Hypokalemia and alkalosis both promote cardiac arrhythmias via: - Hypokalemia → increased resting membrane potential → increased automaticity, slowed repolarization - Alkalosis → increases digitalis sensitivity, delays repolarization

ECG Findings: - U waves: Prominent (often indicating hypokalemia) - QT prolongation: Increased risk of Torsades de Pointes - ST segment depression: “Sagging” ST in precordial leads - T wave flattening: Especially in lateral leads - Atrial fibrillation: Increased incidence (especially in elderly, CAD) - Premature ventricular contractions (PVCs): May herald life-threatening arrhythmias

Clinical Risk: - Digitalis toxicity: Alkalosis + hypokalemia greatly increase risk of digoxin-induced arrhythmias - Digitalis toxicity manifests as non-paroxysmal atrial tachycardia with AV block, or irregular PVCs - May progress to ventricular fibrillation

Respiratory Manifestations

Mechanism: Metabolic alkalosis suppresses respiratory drive via: - Central chemoreceptor inhibition (H⁺ at carotid/aortic bodies normally drives ventilation) - Alkalosis → reduces pH gradient between blood and CSF - Results in decreased minute ventilation

Clinical Features: - Hypoventilation: Reduced respiratory rate and/or tidal volume - Impaired weaning from mechanical ventilation: Metabolic alkalosis blunts respiratory drive → difficult weaning even if pulmonary function adequate - Patients fail spontaneous breathing trials despite good oxygenation and CO₂ clearance - Mechanism: Respiratory centers expect low pH as stimulus; alkalosis removes this stimulus - Worsening of hypoxemia: Hypoventilation → increased alveolar dead space → reduced PaO₂ - Sleep-disordered breathing: May develop apneic episodes during sleep

Metabolic Effects

Oxygen Delivery Impairment: - Alkalosis shifts oxyhemoglobin dissociation curve to the LEFT (increased Hb-O₂ affinity) - Same PaO₂ → reduced O₂ delivery to tissues - Compounded by anemia, cardiac dysfunction - Clinical significance: Worsening tissue hypoxia despite “normal” PaO₂

Electrolyte Derangements: - Hypokalemia: Almost universally present (see below) - Hypocalcemia (ionized): Alkalosis decreases ionized Ca²⁺ (though total Ca²⁺ normal) - Hypomagnesemia: Frequently concurrent, perpetuates K⁺ wasting and alkalosis

Hypokalemia-Specific Complications: - Muscle weakness, rhabdomyolysis (severe K⁺ < 2 mEq/L) - Cardiac arrhythmias (see above) - Polyuria, nephrogenic diabetes insipidus (from K⁺-induced tubular dysfunction) - Glucose intolerance, hyperglycemia (K⁺ affects insulin secretion) - Hypophosphatemia (K⁺ shifts PO₄ intracellularly)

CNS Manifestations (Severe Alkalosis)

Mechanism: Severe alkalosis (pH > 7.60) causes: - Decreased cerebral blood flow (alkalosis causes cerebral vasoconstriction) - Impaired oxidative metabolism in brain - Decreased CSF pH (blood alkalosis causes relative CSF acidosis, leading to paradoxical CNS effects)

Clinical Features: - Confusion, disorientation, altered mental status - Obtundation, stupor (severe cases) - Hallucinations, agitation - Seizures (rare but life-threatening) - Coma (in most severe cases)

Step 1: Confirm Metabolic Alkalosis

ABG Analysis: - Arterial pH > 7.45 (alkalemia) - HCO₃⁻ > 26 mEq/L (elevated) - PCO₂ variable (normal, low, or even slightly elevated depending on compensation)

Step 2: Assess Respiratory Compensation

Calculate Expected PCO₂:

Using Winter’s formula: - Expected PCO₂ = 0.9 × [HCO₃⁻] + 16 ± 2

Interpretation: - Measured PCO₂ matches expected: Pure metabolic alkalosis (appropriate respiratory compensation) - Measured PCO₂ < expected: Concurrent respiratory alkalosis (e.g., hypoxemia triggering hyperventilation despite alkalosis) - Suggests dual acid-base disturbance - May indicate pulmonary pathology (PE, pneumonia, anxiety) - Measured PCO₂ > expected: Concurrent respiratory acidosis (e.g., COPD with alkalosis) - Suggests dual disturbance - May indicate respiratory failure, depressed respiratory drive from alkalosis

Example: - ABG: pH 7.52, HCO₃⁻ 34, PCO₂ 52 - Expected PCO₂ = 0.9 × 34 + 16 ± 2 = 46.6 ± 2 = 44.6–48.6 - Measured PCO₂ 52 > expected → concurrent respiratory acidosis - Interpretation: Metabolic alkalosis + respiratory acidosis (dual disturbance)

Step 3: Check Urine Chloride (Spot Urine)

Specimen Collection: - Random urine acceptable (no need for 24-hour) - Send for Cl⁻ concentration (lab must process for this)

Critical Cutoff: UCl < 20 vs. > 20 mEq/L

Step 4: Identify Cause (Based on UCl)

If UCl < 20 mEq/L (Chloride-Responsive):

Ask about: - Recent vomiting or NG suction: Duration? Frequency? (most common cause) - Diuretic use: Type, dose, duration? (recent or remote?) - Diarrhea: Especially with certain stools (villous adenoma, congenital chloridorrhea — rare) - Prior hypercapnia: COPD exacerbation recently treated? Mechanical ventilation?

If UCl > 20 mEq/L (Chloride-Resistant):

Measure blood pressure:

WITH HYPERTENSION: - Check plasma renin activity (PRA) and plasma aldosterone concentration (PAC) - Calculate aldosterone-to-renin ratio (ARR) - If ARR elevated (> 20–30) → primary aldosteronism workup - Consider: Cushing syndrome, renovascular HTN, Liddle syndrome, licorice/AME

WITHOUT HYPERTENSION (or normotensive): - Bartter or Gitelman syndrome likely - Check urine calcium (Bartter = hypercalciuria; Gitelman = hypocalciuria) - Check serum Mg²⁺ (Gitelman = hypomagnesemia; Bartter = normal) - Genetic testing if available - Severe hypokalemia (K⁺ < 2.0 mEq/L) → can itself cause chloride-resistant alkalosis - Active diuretic use (still taking medication) - Severe Mg²⁺ depletion

Step 5: Assess Serum Electrolytes

Critical Labs: - Potassium: Nearly 100% of metabolic alkalosis patients have hypokalemia - K⁺ typically 2.5–3.5 mEq/L (severe < 2.5) - Hypokalemia perpetuates alkalosis and poses arrhythmia risk

• Magnesium: Check Mg²⁺ (many patients have concurrent hypomagnesemia)
  • Normal Mg²⁺ 1.8–2.2 mg/dL
  • < 1.5 mg/dL indicates deficiency
  • MUST be repleted; otherwise K⁺ repletion will fail
• Chloride: Usually low-normal or low (Cl⁻ typically 95–103 mEq/L)
  • Low Cl⁻ confirms chloride depletion
• Sodium: Usually normal or high-normal
  • May be elevated if volume-depleted
  • May be low if SIADH concurrent (rare)

Step 6: Review Medications and Clinical Context

Medication Review: - Current and recent diuretics? (loop, thiazide, K⁺-sparing?) - PPIs? (increase Ca²⁺ absorption, promote milk-alkali syndrome) - NSAIDs? (reduce renal perfusion, promote renin release) - Licorice-containing products? - Digoxin? (risk of toxicity if hypokalemic + alkalosis)

Clinical Context: - ICU vs. ward setting? - Mechanical ventilation? Recent extubation? - GI pathology (vomiting, NG tube)? - Heart failure, liver disease, renal disease? - Recent surgery or trauma?

General Principles

Chloride-Responsive Alkalosis Treatment

Chloride-Resistant Alkalosis Treatment

Alkalosis with Volume Overload: Acetazolamide

Indications: - Metabolic alkalosis in patient who CANNOT tolerate or should NOT receive normal saline - Examples: - Heart failure (cannot add extra sodium/volume) - Cirrhosis with ascites (sodium restriction) - Pulmonary edema (volume-overloaded) - ARDS (restricted fluid) - Post-hypercapnic alkalosis (chloride repletion alone insufficient; need urinary HCO₃⁻ wasting)

Mechanism: - Carbonic anhydrase inhibitor - Blocks proximal tubule HCO₃⁻ reabsorption via Na⁺-HCO₃⁻ cotransporter - Promotes HCO₃⁻ excretion in urine - Also causes natriuresis and mild diuresis - Does NOT provide chloride → not suitable for chloride-depletion alkalosis alone

Dosing: - 250–500 mg IV or PO q6–12h - Typical: 500 mg BID - Limit duration to 2–3 days (tachyphylaxis develops)

Monitoring: - ABG q4–6h initially - Serum electrolytes (Na⁺, K⁺, Cl⁻) - Urine output and electrolytes (expect bicarbonaturia)

Caution: - Worsens hypokalemia: K⁺ must be supplemented concurrently - Give KCl 20–40 mEq daily while on acetazolamide - Hyperchloremic acidosis risk: Prolonged use may cause chloride retention and metabolic acidosis - Contraindicated in sulfonamide allergy

Efficacy: - Takes 1–2 hours to take effect - HCO₃⁻ typically drops 3–5 mEq/L per day - Combined with saline (if tolerated) shows faster improvement

Severe Metabolic Alkalosis (pH > 7.60): Emergent Treatment

Management of Hypokalemia-Associated Complications

Muscle Weakness or Rhabdomyolysis (K⁺ < 2.5 mEq/L): - Aggressive IV KCl replacement (20–40 mEq/hour through central line) - Consider ICU monitoring (cardiac, renal, CK) - Risk of hyperkalemia as K⁺ repleted (monitor closely)

Cardiac Arrhythmias: - Continuous cardiac monitoring - Aggressive K⁺ repletion (target K⁺ > 4 mEq/L) - Consider temporary pacing or antiarrhythmic agents if life-threatening - Avoid digoxin if possible (increased toxicity risk)

Polyuria from Hypokalemia-Induced DI: - Resolve with K⁺ repletion - Monitor urine output; expect to decrease as K⁺ corrected - Adequate hydration meanwhile

Metabolic Alkalosis and Mechanical Ventilation

Problem: Hypoventilation from metabolic alkalosis (reduced respiratory drive) prevents weaning from ventilator despite adequate oxygenation and CO₂ clearance.

Mechanism: - Alkalosis suppresses central chemoreceptors - Hypoxemia and hypercarbia no longer drive ventilation - Low respiratory drive → patient fails spontaneous breathing trial

Solution: 1. Correct metabolic alkalosis aggressively: - KCl supplementation (especially if hypokalemic) - Saline if chloride-depleted - Acetazolamide if volume-overloaded 2. Target HCO₃⁻ < 26–28 before weaning attempt 3. Permit mild hypercarbia: Allow PCO₂ 45–50 (permissive hypercapnia) if beneficial 4. Expect reduced spontaneous ventilation initially: Will improve as alkalosis corrects 5. Retry weaning after 24h: Often successful once alkalosis corrected

Metabolic Alkalosis and Heart Failure

Challenge: CHF patients need fluid and sodium restriction (worsens pulmonary edema), but chloride-responsive alkalosis typically requires saline.

Solution: - Acetazolamide: First-line (promotes HCO₃⁻ excretion without saline) - Dose: 500 mg q6–12h - Provides diuresis without worsening hypokalemia if K⁺ supplemented - Loop diuretics: May help in euvolemic or euvolemia-approaching patient - Paradox: Loop diuretics caused the alkalosis initially - But if continued at adjusted dose + KCl + Mg²⁺ replacement, loop diuretics can promote urinary HCO₃⁻ loss - Caution with saline: Use sparingly; risk of pulmonary edema outweighs benefit - Maximize K⁺ and Mg²⁺: Essential for acetazolamide efficacy

Metabolic Alkalosis and Hepatic Encephalopathy

Connection: Alkalosis shifts the NH₃/NH₄⁺ equilibrium toward ammonia (NH₃ is predominant at high pH). NH₃ crosses the BBB readily (small, neutral molecule), while NH₄⁺ does not. Result: Increased ammonia entry into CNS.

Mechanism: - Normal pH ~7.4: NH₃/NH₄⁺ ratio ≈ 1/100 - Alkalotic pH ~7.55: NH₃/NH₄⁺ ratio increases (more NH₃ generated) - Increased CNS ammonia → worsening encephalopathy

Management: - Aggressively correct metabolic alkalosis - Target pH < 7.45, HCO₃⁻ < 26 - Avoid saline if possible (NaCl given in large volumes may increase plasma ammonia) - Acetazolamide preferred (promotes HCO₃⁻ excretion) - Standard encephalopathy measures: Lactulose, rifaxomicin, zinc supplementation, etc. - Monitor ammonia level; should improve as pH corrects

Metabolic Alkalosis Post-Loop Diuretic Use in Heart Failure

Scenario: CHF patient on furosemide 80 mg daily develops metabolic alkalosis.

Pathophysiology: - Furosemide causes Na⁺, K⁺, Cl⁻ wasting - Initially (while on diuretic): Hypercalciuria, hypokalemia, alkalosis develop - After stopping furosemide: Remaining Cl⁻ depletion perpetuates alkalosis - But if continue furosemide (adjusted dose) + KCl + saline (small amounts) → can promote recovery

Management: - Do NOT abruptly stop diuretic (will decompensate CHF) - Gentle saline: 100–150 mL/hour NS only if euvolemic/nearing euvolemia - KCl replacement: 40–60 mEq daily - Mg²⁺ repletion: If Mg²⁺ low - Consider spironolactone: Aldosterone antagonism + K⁺-sparing → reduces ongoing H⁺ wasting - Target: HCO₃⁻ < 26, pH < 7.45

Milk-Alkali Syndrome: Management

See detailed section above, but key points: 1. Discontinue alkali and excess calcium: Complete cessation 2. Hydration: Adequate NS to promote calciuria 3. Loop diuretic + hydration: Furosemide to promote urine calcium excretion 4. Corticosteroids: If renal function severely impaired (prednisone 20–40 mg daily) 5. Monitor: Serum calcium, Cr, HCO₃⁻ closely 6. Resolve alkalosis slowly: Allow 3–5 days for normalization